Lisanti Capital Growth’s Ionis Pharmaceuticals IONS Stock Holding History

Lisanti Capital Growth’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,699	Closed	-$5.68M	–	129
2026 Q1	$5.68M	Buy	75,699 +42,910	+131%	+$3.39M	1.43%	23
2025 Q4	$2.59M	Sell	32,789 -59,335	-64%	-$4.47M	0.61%	74
2025 Q3	$6.03M	Buy	+92,124	New	+$4.5M	1.47%	18
2024 Q3	–	Sell	-10,845	Closed	-$517K	–	133
2024 Q2	$517K	Sell	10,845 -16,990	-61%	-$697K	0.12%	114
2024 Q1	$1.21M	Sell	27,835 -34,580	-55%	-$1.65M	0.29%	102
2023 Q4	$3.16M	Buy	+62,415	New	+$2.99M	0.74%	62
2015 Q1	–	Sell	-36,805	Closed	-$2.27M	–	96
2014 Q4	$2.27M	Sell	36,805 -1,820	-5%	-$89.8K	1.14%	41
2014 Q3	$1.5M	Buy	+38,625	New	+$1.37M	0.75%	62
2014 Q1	–	Sell	-57,115	Closed	-$2.27M	–	113
2013 Q4	$2.27M	Buy	57,115 +39,390	+222%	+$1.4M	0.96%	52
2013 Q3	$665K	Buy	+17,725	New	+$529K	0.3%	95

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Lisanti Capital Growth's IONS Position: Q2 2026 in Review

Lisanti Capital Growth sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 75,699 shares — an estimated $5.68M sold.

Lisanti Capital Growth first reported a position in IONS in Q3 2013 and held it in 10 quarters. The position peaked at $6.03M in Q3 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Lisanti Capital Growth reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Lisanti Capital Growth sold 75,699 Ionis Pharmaceuticals shares in Q2 2026, an estimated $5.68M.
Lisanti Capital Growth first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Lisanti Capital Growth's Ionis Pharmaceuticals position peaked at $6.03M in Q3 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.